Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Laura J.P. Latimer"'
Autor:
S. van Drunen Littel-van den Hurk, Ravendra Garg, Andrew A. Potter, Susantha Gomis, Laura J.P. Latimer, Volker Gerdts
Publikováno v:
Antiviral Research. 162:54-60
Human parainfluenza virus 3 (PIV3) and respiratory syncytial virus (RSV) are major causative agents of serious respiratory tract illness in newborns and infants. Maternal vaccination could be a promising approach to provide immediate protection again
Autor:
S. van Drunen Littel-van den Hurk, Volker Gerdts, Andrew A. Potter, Ravendra Garg, Robert Brownlie, Laura J.P. Latimer
Publikováno v:
Vaccine. 35:7139-7146
Human parainfluenza virus type 3 (PIV3) is a major cause of lower respiratory disease i.e. bronchitis, bronchiolitis or pneumonia, in infants and young children. Presently there is no licensed vaccine against PIV3. To produce an effective subunit vac
Autor:
Volker Gerdts, Ravendra Garg, Andrew A. Potter, S. van Drunen Littel-van den Hurk, Laura J.P. Latimer
Publikováno v:
Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is the most common cause of respiratory tract infections in both children and elderly people. In this study we evaluated the short- and long-term protective efficacy of a single intranasal (IN) immunization with a RS
Autor:
Ravendra Garg, Y. Wang, Volker Gerdts, Elemir Simko, S. van Drunen Littel-van den Hurk, Andrew A. Potter, Laura J.P. Latimer
Publikováno v:
Vaccine. 34:261-269
Respiratory syncytial virus (RSV) is the causative agent of serious upper and lower respiratory tract infections in newborns and infants. Protection from RSV is crucial for neonates, and maternal immunization is one approach that holds promise for pr
Autor:
Laura J.P. Latimer, Robert Brownlie, Andrew A. Potter, Volker Gerdts, S. van Drunen Littel-van den Hurk, Ravendra Garg
Publikováno v:
Antiviral research. 158
Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are major causes of serious lower respiratory tract disease in infants. Currently there is no licensed vaccine against RSV or PIV3. To make an effective bivalent subunit va
Autor:
Volker Gerdts, S. van Drunen Littel-van den Hurk, Andrew A. Potter, Laura J.P. Latimer, Ravendra Garg
Publikováno v:
Journal of General Virology. 95:1043-1054
Respiratory syncytial virus (RSV) is one of the primary causative agents of upper and lower respiratory tract infections in young children, in particular infants. Recently, we reported the protective efficacy of a RSV vaccine formulation consisting o
Autor:
Volker Gerdts, Ravendra Garg, S. van Drunen Littel-van den Hurk, Laura J.P. Latimer, Andrew A. Potter
Publikováno v:
Vaccine. 33(11)
Respiratory syncytial virus (RSV) causes severe respiratory illness in infants. There are no licensed vaccines to prevent RSV infection. The neonate receives short-term protection from maternally derived antibodies, which, however, can also interfere
Autor:
Ethel Atanley, Sam K. Attah-Poku, Jennifer Kovacs-Nolan, Lorne A. Babiuk, Laura J.P. Latimer, Sarah Mackenzie-Dyck, Sylvia van Drunen Littel-van den Hurk
Publikováno v:
Clinical and vaccine immunology : CVI. 22(1)
Protective efficacy against bovine herpesvirus 1 (BoHV-1) has been demonstrated to be induced by a plasmid encoding bovine neutrophil beta-defensin 3 (BNBD3) as a fusion construct with truncated glycoprotein D (tgD). However, in spite of the increase
Autor:
B. I. Loehr, Reno Pontarollo, Robert Rankin, Laura J.P. Latimer, S. van Drunen Littel-van den Hurk, Lorne A. Babiuk, P. Willson
Publikováno v:
Journal of General Virology. 82:3035-3043
DNA vaccines have several advantages over conventional vaccines. One of the most important characteristics is the presentation of antigen via both MHC class I and class II receptors. Although this generally results in strong T-cell responses, antibod
Autor:
Andrew A. Potter, Ravendra Garg, Elemir Simko, S. van Drunen Littel-van den Hurk, Volker Gerdts, Laura J.P. Latimer
Publikováno v:
The Journal of general virology. 95(Pt 2)
The majority of infections, including those caused by respiratory syncytial virus (RSV), occur at mucosal surfaces. As no RSV vaccine is available our goal is to produce an effective subunit vaccine with an adjuvant suitable for mucosal delivery and